Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.
“Our expansion into the U.S. in one of the world’s preeminent biotechnology hubs is an important step as we transition to a clinical-stage company with our first Bicycle Drug Conjugate program for oncology entering clinical testing next year,” said Kevin Lee, Ph.D., chief executive officer of Bicycle Therapeutics. “Ros brings proven experience in business development, finance, operations and commercial development.”
Deegan joined Bicycle Therapeutics from Trevena, where she most recently served on the senior leadership team as senior vice president, Business Development and Operations, and previously held the role of head of Finance and Operations. Prior to joining Trevena, Deegan was director of Business Development at GSK in the U.S. and, prior to that, she served as director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis.
“I am excited to join Bicycle, which has strong potential to create a new class of drugs with important advantages in delivering toxins to tumours, and broad applicability in a range of therapeutic areas,” said Deegan. “Bicyclic peptides hold the potential to deliver greater potency, specificity and penetration than current modalities, with more rapid clearance from the body. Our U.S. operations will play a central role for Bicycle as we advance our near-term oncology programs and enter collaborations across a range of diseases.”